Premium
PCSK9 is required for the disposal of non‐acetylated intermediates of the nascent membrane protein BACE1
Author(s) -
Jonas Mary Cabell,
Costantini Claudio,
Puglielli Luigi
Publication year - 2008
Publication title -
embo reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.584
H-Index - 184
eISSN - 1469-3178
pISSN - 1469-221X
DOI - 10.1038/embor.2008.132
Subject(s) - acetylation , membrane , chemistry , membrane protein , microbiology and biotechnology , biochemistry , business , biology , gene
We have recently identified a new form of post‐translational regulation of BACE1 (β‐site amyloid precursor protein (APP)‐cleaving enzyme 1), a membrane protein that acts as the rate‐limiting enzyme in the generation of the Alzheimer disease amyloid β‐peptide (Aβ). Specifically, BACE1 is transiently acetylated on seven lysine residues in the lumen of the endoplasmic reticulum/endoplasmic reticulum–Golgi intermediate compartment (ER/ERGIC). The acetylated intermediates of the nascent protein are able to reach the Golgi apparatus, whereas the non‐acetylated ones are retained and degraded in a post‐ER compartment. Here, we report that the serine protease PCSK9 (proprotein convertase subtilisin kexin type 9) contributes to the disposal of non‐acetylated BACE1. Both overexpression and small interfering RNA‐mediated downregulation of PCSK9 affected the levels of BACE1. The downregulation of PCSK9 affected the levels of the loss‐of‐acetylation mutants (BACE1 Ala and BACE1 Arg ) but not those of the gain‐of‐acetylation mutant (BACE1 Gln ). In addition, Pcsk9 −/− mice showed increased levels of BACE1 and Aβ in the brain. Finally, we found that nascent low‐density lipoprotein receptor, a known substrate of PCSK9, is also acetylated.